Collegium Pharmaceutical(COLL) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca Revenue of $53.2 Million and Record Xtampza ER Revenue of $49.5 Million – – Achieved Q3'24 GAAP Net Income of $9.3 Million – – Delivered Record Q3'24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Ch ...